Literature DB >> 30117059

Pompe Disease: From Basic Science to Therapy.

Lara Kohler1, Rosa Puertollano2, Nina Raben3.   

Abstract

Pompe disease is a rare and deadly muscle disorder. As a clinical entity, the disease has been known for over 75 years. While an optimist might be excited about the advances made during this time, a pessimist would note that we have yet to find a cure. However, both sides would agree that many findings in basic science-such as the Nobel prize-winning discoveries of glycogen metabolism, the lysosome, and autophagy-have become the foundation of our understanding of Pompe disease. The disease is a glycogen storage disorder, a lysosomal disorder, and an autophagic myopathy. In this review, we will discuss how these past discoveries have guided Pompe research and impacted recent therapeutic developments.

Entities:  

Keywords:  Glycogen storage; autophagy; enzyme replacement therapy; lysosome; myopathy; newborn screening

Mesh:

Year:  2018        PMID: 30117059      PMCID: PMC6277280          DOI: 10.1007/s13311-018-0655-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  169 in total

1.  Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.

Authors:  Baodong Sun; Haoyue Zhang; Luis M Franco; Talmage Brown; Andrew Bird; Ayn Schneider; Dwight D Koeberl
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

2.  The African origin of the common mutation in African American patients with glycogen-storage disease type II.

Authors:  J A Becker; J Vlach; N Raben; K Nagaraju; E M Adams; M M Hermans; A J Reuser; S S Brooks; C J Tifft; R Hirschhorn; M L Huie; M Nicolino; P H Plotz
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

3.  Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Authors:  Mai K Elmallah; Darin J Falk; Sushrusha Nayak; Roland A Federico; Milapjit S Sandhu; Amy Poirier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

4.  Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.

Authors:  David F Kronn; Debra Day-Salvatore; Wuh-Liang Hwu; Simon A Jones; Kimitoshi Nakamura; Torayuki Okuyama; Kathryn J Swoboda; Priya S Kishnani
Journal:  Pediatrics       Date:  2017-07       Impact factor: 7.124

5.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

Review 6.  Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.

Authors:  Benedikt Schoser; Andrew Stewart; Steve Kanters; Alaa Hamed; Jeroen Jansen; Keith Chan; Mohammad Karamouzian; Antonio Toscano
Journal:  J Neurol       Date:  2016-07-02       Impact factor: 4.849

7.  Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.

Authors:  Ilaria Basile; Afitz Da Silva; Khaled El Cheikh; Anastasia Godefroy; Morgane Daurat; Alice Harmois; Marc Perez; Catherine Caillaud; Henry-Vincent Charbonné; Bernard Pau; Magali Gary-Bobo; Alain Morère; Marcel Garcia; Marie Maynadier
Journal:  J Control Release       Date:  2017-11-03       Impact factor: 9.776

8.  Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.

Authors:  S O Kyosen; S Iizuka; H Kobayashi; T Kimura; T Fukuda; J Shen; Y Shimada; H Ida; Y Eto; T Ohashi
Journal:  Gene Ther       Date:  2009-12-24       Impact factor: 5.250

9.  Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; W Henley; K M Wyatt; V Nikolaou; S Waldek; D A Hughes; R H Lachmann; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-06-07       Impact factor: 4.982

10.  Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

Authors:  Suhrad G Banugaria; Sean N Prater; Trusha T Patel; Stephanie M Dearmey; Christie Milleson; Kathryn B Sheets; Deeksha S Bali; Catherine W Rehder; Julian A J Raiman; Raymond A Wang; Francois Labarthe; Joel Charrow; Paul Harmatz; Pranesh Chakraborty; Amy S Rosenberg; Priya S Kishnani
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

View more
  41 in total

1.  Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants.

Authors:  Paula Hernández-Arévalo; José D Santotoribio; Rocío Delarosa-Rodríguez; Antonio González-Meneses; Salvador García-Morillo; Pilar Jiménez-Arriscado; Juan M Guerrero; Hada C Macher
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

Review 2.  Challenges in treating Pompe disease: an industry perspective.

Authors:  Hung V Do; Richie Khanna; Russell Gotschall
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

4.  Myopathy: Recent Progress, Current Therapies, and Future Directions.

Authors:  Andrew L Mammen; Ricardo H Roda; Doris G Leung
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Improved efficacy of a next-generation ERT in murine Pompe disease.

Authors:  Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna
Journal:  JCI Insight       Date:  2019-03-07

Review 6.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

Review 7.  Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.

Authors:  Gerben J Schaaf; Rodrigo Canibano-Fraile; Tom J M van Gestel; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Ann Transl Med       Date:  2019-07

8.  Uptake of moss-derived human recombinant GAA in Gaa -/- mice.

Authors:  Stefan Hintze; Paulina Dabrowska-Schlepp; Birgit Berg; Alexandra Graupner; Andreas Busch; Andreas Schaaf; Benedikt Schoser; Peter Meinke
Journal:  JIMD Rep       Date:  2021-02-01

Review 9.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

10.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.